158 related articles for article (PubMed ID: 12773076)
41. [Tenofovir: pharmacology and interactions].
Azanza JR; García Quetglas E; Sádaba B; Gómez-Giu A
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():2-6. PubMed ID: 19195431
[TBL] [Abstract][Full Text] [Related]
42. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Hazra R; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty JF; Yale K; Poblenz M; Kearney BP; Zhong L; Coakley DF; Blanche S; Bresson JL; Zuckerman JA; Zeichner SL
Antimicrob Agents Chemother; 2004 Jan; 48(1):124-9. PubMed ID: 14693529
[TBL] [Abstract][Full Text] [Related]
43. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Cihlar T; Birkus G; Greenwalt DE; Hitchcock MJ
Antiviral Res; 2002 Apr; 54(1):37-45. PubMed ID: 11888656
[TBL] [Abstract][Full Text] [Related]
44. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M
J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601
[TBL] [Abstract][Full Text] [Related]
45. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
47. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
48. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
49. Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Blanchard JN; Wohlfeiler M; Canas A; King K; Lonergan JT
Clin Infect Dis; 2003 Sep; 37(5):e57-62. PubMed ID: 12942419
[TBL] [Abstract][Full Text] [Related]
50. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
51. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Winston A; Pozniak A; Mandalia S; Gazzard B; Pillay D; Nelson M
AIDS; 2004 Apr; 18(6):949-51. PubMed ID: 15060444
[No Abstract] [Full Text] [Related]
52. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
[TBL] [Abstract][Full Text] [Related]
54. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Uglietti A; Zanaboni D; Gnarini M; Maserati R
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
[TBL] [Abstract][Full Text] [Related]
55. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
56. Correction: tenofovir disoproxil fumarate.
Nestor RJ
Ann Pharmacother; 2003; 37(7-8):1148. PubMed ID: 12841837
[No Abstract] [Full Text] [Related]
57. Prodrug of tenofovir diphosphate approved for combination HIV therapy.
Thompson CA
Am J Health Syst Pharm; 2002 Jan; 59(1):18. PubMed ID: 11813460
[No Abstract] [Full Text] [Related]
58. In vivo study of the effect of antiviral acyclic nucleotide phosphonate (R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA, tenofovir) and its prodrug tenofovir disoproxil fumarate on rat microsomal cytochrome P450.
Anzenbacherová E; Anzenbacher P; Zídek Z; Buchar E; Kmoníčková E; Potmesil P; Nekvindová J; Veinlichová A; Holý A
Physiol Res; 2008; 57(5):761-768. PubMed ID: 17949244
[TBL] [Abstract][Full Text] [Related]
59. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Smith PF; Kearney BP; Liaw S; Cloen D; Bullock JM; Haas CE; Yale K; Booker BM; Berenson CS; Coakley DF; Flaherty JF
Pharmacotherapy; 2004 Aug; 24(8):970-7. PubMed ID: 15338845
[TBL] [Abstract][Full Text] [Related]
60. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Wainberg MA; Miller MD; Quan Y; Salomon H; Mulato AS; Lamy PD; Margot NA; Anton KE; Cherrington JM
Antivir Ther; 1999; 4(2):87-94. PubMed ID: 10682153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
